Direkt zum Inhalt
Merck

50359

Sigma-Aldrich

Voglibose

≥97.0% (TLC)

Synonym(e):

3,4-Dideoxy-4-{[2-hydroxy-1-(hydroxymethyl)-ethyl]-amino]-2-D-epi-inosit, N-(1,3-Dihydroxyprop-2-yl)-valiolamin

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Empirische Formel (Hill-System):
C10H21NO7
CAS-Nummer:
Molekulargewicht:
267.28
MDL-Nummer:
UNSPSC-Code:
12352201
PubChem Substanz-ID:
NACRES:
NA.25

Biologische Quelle

synthetic

Qualitätsniveau

Assay

≥97.0% (TLC)

Form

powder

Farbe

white

Lagertemp.

−20°C

SMILES String

OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O

InChI

1S/C10H21NO7/c12-2-5(3-13)11-6-1-10(18,4-14)9(17)8(16)7(6)15/h5-9,11-18H,1-4H2/t6-,7-,8+,9-,10-/m0/s1

InChIKey

FZNCGRZWXLXZSZ-CIQUZCHMSA-N

Angaben zum Gen

Anwendung

Voglibose is an α-glucosidase inhibitor, similar to acarbose and miglitol, used for lowering post-prandial hyperglycemia (PPHG) in people with diabetes mellitus. Voglibose is used to study it benefits as a protectant against ischemia-reperfusion injury through glucagon-like peptide 1 receptors and the phosphoinositide 3-kinase-Akt-endothelial nitric oxide synthase pathway.

Verpackung

Bottomless glass bottle. Contents are inside inserted fused cone.

Sonstige Hinweise

To gain a comprehensive understanding of our extensive range of Monosaccharides for your research, we encourage you to visit our Carbohydrates Category page.

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Persönliche Schutzausrüstung

Eyeshields, Gloves, type N95 (US)


Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Y Iwamoto et al.
Diabetes, obesity & metabolism, 12(8), 700-708 (2010-07-02)
To confirm the efficacy of vildagliptin in patients with type 2 diabetes (T2D) by testing the hypothesis that glycosylated haemoglobin (HbA1c) reduction with vildagliptin is superior to that with voglibose after 12 weeks of treatment. In this 12-week, randomized, double-blind
Clement Lo et al.
The Cochrane database of systematic reviews, 9, CD011798-CD011798 (2018-09-25)
Diabetes is the commonest cause of chronic kidney disease (CKD). Both conditions commonly co-exist. Glucometabolic changes and concurrent dialysis in diabetes and CKD make glucose-lowering challenging, increasing the risk of hypoglycaemia. Glucose-lowering agents have been mainly studied in people with
Bum-Ho Bin et al.
Experimental dermatology, 22(8), 541-546 (2013-07-25)
Overproduction of melanin can lead to medical disorders such as postinflammatory melanoderma and melasma. Therefore, developing antimelanogenic agents is important for both medical and cosmetic purposes. In this report, we demonstrated for the first time that the antidiabetic drug voglibose
R Kawamori et al.
Diabetes, obesity & metabolism, 14(4), 348-357 (2011-12-08)
To evaluate the efficacy and safety of linagliptin 5 and 10 mg vs. placebo and voglibose in Japanese patients with type 2 diabetes mellitus (T2DM). This study enrolled patients with inadequately controlled T2DM who were previously treated with one or
E Araki et al.
Diabetes, obesity & metabolism, 15(4), 364-371 (2012-11-21)
In a phase III study conducted among Japanese patients with type 2 diabetes mellitus (T2DM), linagliptin 5 and 10 mg showed clinically meaningful improvements in glycaemic parameters after 12 and 26 weeks compared with placebo and voglibose, respectively. This extension study assessed

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.